Krystal Biotech, Inc. (KRYS) SEC Filings & Earnings Calls

Pricing and reimbursement negotiations in Europe could impact international revenue

“Pricing discussions in Germany and France ongoing; expected to continue into 2H 2026 and 2027”

Pipeline dependency on clinical trial outcomes

“Multiple clinical data readouts expected in 2H 2026; registrational studies for KB803, KB801, KB407”

US VYJUVEK sales decline

“partially offset by a reduction in United States VYJUVEK sales.” · word for word

Dependence on VYJUVEK for revenue

“Product revenue, net was $119.2 million for the three months ended June 30, 2026, as compared to $96.0 million for the three months ended June 30, 2025. The increase in product revenue, net was driven by an increase in VYJUVEK sales” · word for word

Disclosure is based on a single patient from a discontinued study; no statistical significance or regulatory implications

“The Company did not previously disclose the single-patient observation described above and is making this disclosure now solely to ensure that all investors and other stakeholders have equal access to it” · word for word

Clinical trial cost unpredictability

“Costs related to clinical trials can be unpredictable and, therefore, there can be no guarantee that we will have sufficient capital to fund the continued or planned pre-clinical and clinical studies for our product candidates or our operations.” · word for word

Revenue fluctuation risk

“We expect our future revenue to fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any product sales.” · word for word

Single product dependency

“VYJUVEK is currently the only approved product; pipeline candidates are still in clinical trials.”

Litigation risk related to director compensation

“A stockholder filed a derivative complaint alleging excessive non-employee director compensation. Settlement reached in principle.”

Dependence on VYJUVEK commercial success

“We are substantially dependent on the commercial success of VYJUVEK” · word for word

Competition from biosimilars

“VYJUVEK and, if approved, our investigational product candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.” · word for word

Product liability risk

“If any product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of VYJUVEK or our product candidates.” · word for word

Negative public perception of gene therapy

“Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our gene therapy product or product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.” · word for word

Healthcare reform and drug pricing pressure

“Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.” · word for word

European pricing negotiations ongoing; potential delays in reimbursement and launch.

“Pricing discussions with German and French reimbursement authorities are ongoing. The Company expects negotiations to continue until at least 2H 2026 in Germany and until at least 2027 in France.” · word for word

Clinical trial risk for pipeline assets; KB408 and KB803 still in development.

“The Company continues to enroll patients in the repeat dose Cohort 2B of SERPENTINE-1” · word for word

Dependence on single product VYJUVEK; pipeline still in clinical stages.

“VYJUVEK is the only commercial product; pipeline programs are in Phase 2/3 or preclinical.”

Global expansion execution risk; regulatory approvals in new markets.

“Launch VYJUVEK in at least one more major European market and expand specialty distributor network to cover over 40 countries.” · word for word

Clinical trial risk remains; one serious adverse event (asthma exacerbation) deemed procedure-related, not drug-related.

“One serious adverse event (SAE) of asthma exacerbation was reported 24 hours after completion of the bronchoscopy. The SAE was deemed procedure related, and not related to KB407.” · word for word

European pricing negotiations could delay revenue ramp.

“Pricing negotiations in Germany expected until at least 2H 2026; France negotiations 15+ months.”

Pipeline dependency on clinical trial outcomes.

“CF interim data expected in Q4; AATD data in 1H 2026; ophthalmology studies enrolling.”

Dependence on single product VYJUVEK

“Our operating profitability is dependent upon the continued successful commercialization of VYJUVEK, our U.S. Food and Drug Administration (“FDA”), European Commission (“EC”), and Japan’s Ministry of Health, Labour, and Welfare (“MHLW”) approved product, as well as successful development, approval and commercialization of our product candidates.” · word for word

Need for additional funding for pipeline

“We may need to obtain substantial additional funding in order to receive regulatory approval and to commercialize our product candidates.” · word for word